華潤醫藥(03320.HK)附屬夥河南真實生物科技戰略合作
華潤醫藥(03320.HK)公佈,其間接擁有59.99%權益的非全資附屬華潤雙鶴(600062.SH)已於近期與河南真實生物科技訂立爲期十年的戰略合作協議,雙方將在產品研發、生產、經銷以及與經銷直接相關的多個方面、領域拓展合作。
戰略合作協議項下的具體合作細節將須待華潤雙鶴與河南真實生物科技按照各項目實際內容另行商定。
公司認爲,與河南真實生物科技的戰略合作與集團未來發展戰略及經營需求一致,並符合公司及其股東的整體利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.